Список литературы
| 1 | Андреева Г.М. Психология социального познания: Учебное пособие для студентов вузов. - 3-е изд., перераб. и доп. - М.: Аспект Пресс, 2005 |
| 2 | Андреева Г.М. Социальная психология: Учебник для вузов. - М.: Аспект Пресс, 2001 |
| 3 | Базин И.С. Рак толстой кишки - состояние проблемы / И.С. Базин, А.М.Тарин, С.А. Жарков// Рус. мед. журн.- 2003- №11 - с.674 |
| 4 | Бальцерович Л. Социализм, капитализм, трансформация: Очерки на рубеже эпох/ Пер, с польского. - М.: Наука/УРАО, 1999 |
| 5 | Барулин B.C. Социально-философская антропология. Человек и общественный мир. - М.: Академический проект; Альма Матер, 2007.Барулин B.C. Социально-философская антропология. Человек и общественный мир. - М.: Академический проект; Альма Матер, 2007. |
| 6 | Бергер Петер Л., Бергер Бриджит, Коллинз Р. Личностно-ориентиро-ванная социология. - М.: Академический проект, 2004 |
| 7 | Бережная М., Асп. А-К. Подросток - наше будущее/Итоги 10-летнего российско-шведского сотрудничества в области охраны здоровья подростков - СПб.: Моби Дик, 2007 |
| 8 | Бехер О.А., Слонимская Е.М., Куприянова И.Е. Уровень тревоги у женщин, страдающих раком молочной железы. Сиб онкол журн. 2008;(2):26-7. |
| 9 | Блауберг И.В., Юдин Э.Г., Становление и сущность системного. М., 1973. стр. 164-165. |
| 10 | Васильева Л.А. Делаем новости!/Учебное пособие. - М.: Аспект Пресс, 2002 |
| 11 | Величковский Ю.Т. Жизнеспособность нации. Роль социального стресса и генетических процессов в популяции развития демографического кризиса и изменения состояния здоровья населения россии - М., 2009 - 176 с. |
| 12 | Вишневский А.Г., Андреев Е.М. и др. Демографическая модернизация России, 1900- 2000. Под ред. Вишневского А.Г. М.: Новое издательство, 2006 - 608 с. |
| 13 | Владимирская ЕБ., МасчанАА, Румянцев А.Г.Апоптоз и его роль в развитии опухолевого роста. Гематол. и трансфузиол. 1997; 42 (5): 4-9. |
| 14 | Власов В.В. Эффективность диагностических исследований. – М.: Медицина, 1988.-256 с. |
| 15 | Гарин A.M., Базин И.С. Десять наиболее распространенных злокачественных опухолей. М., 2006. |
| 16 | Герасименко В.Н., Тхостов А.Ш. Психологические и деонтологические аспекты реабилитации онкологических больных. Клин психоонкол 2002; (2). |
| 17 | Гидденс Э. Социология/При участии К. Бердсолл: Пер. с англ. 2-е изд., полностью перераб. и доп. - М.: Эдиториал УРСС, 2005 |
| 18 | Глазунов И.С. Руководство по профилактике в практическом здравоохранении адаптированный вариант рекомендации ВОЗ "Prevention in primary care"/ под ред. И.С. Глазунова, Р.Т. Оганова и др. - М., - 2000 - 87с. |
| 19 | Гобозов И.А. Социальная философия: учебник для вузов. - М.: Академический проект, 2007 |
| 20 | Голубков Е.П. Использование системного анализа в отраслевом планировании. - М., 1977 - 135с. |
| 21 | Гонтмахер Е.Ш. Социальная политика: уроки 90-х. - М.: Гелиос АРВ, 2000 |
| 22 | Гражданское общество: теория, история, современность/Отв. ред. З.Т. Голенкова. - М.: ИС РАН, 1999 |
| 23 | Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2008 г. Вести РОНЦ им. Н.Н. БлохинаРАМН 2010;2(Прил 1):55-6. |
| 24 | Джудит Л. Социальный капитал и социальное расслоение в современной России/Под ред. Джудит Л. Твигг и Кэйт Шектор. - М.: Алышна Паблишер, 2003 |
| 25 | Дзялошинский И.М. Методы деятельности СМИ в условиях становления гражданского общества: Учебное пособие. - М.: Пульс, 2000 |
| 26 | Дзялошинский И.М. Формы и методы работы журналиста с источником информации: Учебное пособие. - М.: Пульс, 2001 |
| 27 | Еремин В.А. Прогностические признаки колоректального рака /В.А. Еремин - Ставрополь, 2007 - 135с. |
| 28 | Жуков В.И. Российские преобразования: социология, экономика, политика. - М.: Академический проект, 2003 |
| 29 | Заридзе Д.Г. Эпидемиология, механизмы канцерогенеза и профилактика рака /Д.Г. Заридзе/ Проблемы клинической онкологии 2005 - №2 - с.10-16 |
| 30 | Заславская Т.И. Социетальная трасформация российского общества. - М.: Дело, 2002 |
| 31 | Земляной В. П., Трофимова Т. Н., Непомнящая С. Л., Дементьева Т. В. // Практ. онкол. - 2005. - Т. 6, № 2. - С. 71—80. |
| 32 | Земляной В. П., Трофимова Т. Н., Непомнящая С. Л., Дементьева Т. В. // Практ. онкол. - 2005. - Т. 6, № 2. - С. 71—80. |
| 33 | Зубаревич Н.В. Социальное развитие регионов России: проблемы и тенденции переходного периода. - М.: Эдиториал УРСС, 2003 |
| 34 | Иванов П.М., "колоректальный рак" (профилактика и ранняя диагностика) метод рек / П.М. Иванов, В.Г. Игнатьев, Т.Н. Жарникова// - Якутск, 2007 - 9с. |
| 35 | Изменяющаяся Россия в зеркале социологии/Под ред. М.К. Горшкова, Н.Е. Тихоновой. - М.: Летний сад, 2004 |
| 36 | Казначеев В.П., Баевский Р.М., Берсенева А.П. Донозологическая диагностика в практике массовых обследований населения.-Л.: Медицина, 1980.-207 с. |
| 37 | Каминская А.А.Формы профилактической работы медицинских учреждений / А.А, Каминская, О.П. Королев, Л.А., Бальзамова и др.// Пробл. Соц. Гигиены, здр. И истории медицины - 2005 -№3 - с. 29-31. |
| 38 | Кемеров В.Е. Введение в социальную философию: Учебник для вузов. 4-е изд., испр. - М.: Академический проект, 2001 |
| 39 | Ким М.Н. Журналистика: методология профессионального творчества. - СПб: Изд-во Михайлова В.А., 2004 |
| 40 | Клиническая маммология (практическое руководство). Под ред. М.И. Давыдова и В.П. Летягина. М.: АБВ-пресс, 2010; с. 110-1. |
| 41 | Клямкин И., Тимофеев Л. Теневая Россия. - М.: РГГУ, 2000 |
| 42 | Кучеренко В.З., Сырцова Л.Е. Проблемы профилактики в условиях реформ здравоохранения.// Проблемы соц. Гигиены и истории мед. - М., 1999 - №1 - с.42-43. |
| 43 | Лазутина Г.В. Основы творческой деятельности журналиста: Учебник для студентов вузов. - 2-е изд., перераб. и доп. - М.: Аспект Пресс, 2004 |
| 44 | Лазутина Г.В. Профессиональная этика журналиста: Учебное пособие по журналистике. - М.: Аспект Пресс, 1999 |
| 45 | Лазутина Г.В., Распопова С.С. Жанровые разновидности журналистского творчества: Учебное пособие. - М.: Аспект Пресс, 2009 |
| 46 | Лащук О.Р. Редактирование информационных сообщений: Учебное пособие для студентов вузов. - М.: Аспект Пресс, 2004 |
| 47 | Левшин В.Ф., Влияние "группы риска" при ранней диагностике злокачественных новообразований/ В.Ф. Левшин, Д.Г. Заридзе// Вопросы онкологии - 1990 -№3 - с. 286-290. |
| 48 | Летягин В.П. Опухоли молочных желез у мужчин. Маммология 2006;(2):13-20. |
| 49 | Лига М.Б. Качество жизни как основа социальной безопасности. -М.: Гардарики, 2006 |
| 50 | Лисицын Ю.П., Полунина Н.В. Общественное здоровье и здравоохранение// Учебник для медицинских ВУЗОВ - М. : Медицина, - 2002 - с. 382. |
| 51 | Лукина М.М. Современные журналистские технологии в работе с новостями: Учебное пособие. - М.: Пульс, 2001 |
| 52 | Лукина М.М. Технология интервью: Учебное пособие для вузов. -М.: Аспект Пресс, 2003 |
| 53 | Льюис К.С. Любовь. Страдание. Надежда: Притчи. Трактаты/Пер, с англ. - М.: Республика, 1992 |
| 54 | Любченко Л.Н., Портной С.М., Поспе-хова Н.И. и др. Клинико-молекулярные аспекты наследственного рака молочной железы. Молекул мед 2007;(1):8-9. 6. Любченко Л.Н. Наследственный рак молочной железы и яичников: ДНК-диагностика, индивидуальный прогноз, лечение и профилактика. Автореф. дис. ... д-ра мед. наук. М.. 2009. 1'. Friedman |
| 55 | Майерс Д. Социальная психология/Пер, с англ. - СПб.: Питер, 1996 |
| 56 | Мальцев В.Н. Опыт создания региональной системы профилактики заболеваний. // Проблемы соц. , здр. И истории мед. - 2001 - №4 - С. 41-42. |
| 57 | Массовые медицинские обследования: Пер. с англ.-М.: Медицина.-1975.-117 с. |
| 58 | Михайлова Ю.В. Предотвратимая смертность в России и пути её снижения/ под ред. Михайловой Ю.В., Ивановой А.Е. - М, 2006 -132 с. |
| 59 | Михайлова Ю.В. Российская смертность в геополитических коордтнатах / Ю.В. Михайлова// Профилактика заболеваний и укрепление здоровья - 2007 - №5 - с.13-15. |
| 60 | Михайлова Ю.В., Еремичва Т.И. Программно-целевой метод - инструмент стратегического планирование в здравоохранении (Сб науч. Трудов республиканской научно-практической конференции "Экономическая эффективность и развитие регионального здравоохранения", 28-30 мая 2002 г.) - М.: ЦНИИОИЗ, 2002,- с.15-18. |
| 61 | Нugo F,Fisher G,Eigenbrodt E.Anticancer res- 1999. |
| 62 | Новгородцев Г.А. и соавт. Диспансеризация населения в СССР - М. Медицина |
| 63 | Новик А.А., Ионова Т.Н., Кайнд П., Концепция исследования качества жизни в медицине. - СПб.: "Элби", 1999 -140с. |
| 64 | Новик А.А., Ионова Т.Н., Никитина Т.П. Концепция исследования качества жизни в педиатрии // Педиатрия. - 2002. - № 6. - C.83-88 |
| 65 | Новик А.А., Ионова Т.Н., Руководство по исследованию качества жизни в медицин - спб., М.: "ОЛМА-ПРЕСС", 2002 - 314с. |
| 66 | Общая социология: Учебное пособие/Под общ. ред. проф. А.Г. Эфен-диева. - М.: ИНФРА-М, 2000 |
| 67 | Оганов Р.Г., Хальнин Р.А., Руководство по медицинской профилактике. - М.: ГЭОТАР-Медна, 2007 - 450 с. |
| 68 | Орлова Г.Г. Учебное пособие по профилактической медицине. М.: - 2003, 123с. |
| 69 | Осадчая Г.И. Социология социальной сферы: Учебное пособие для высшей школы - 2-е изд., перераб. и доп. - М.: Академический проект, 2003 |
| 70 | Осипов Г.В. Социальное мифотворчество и социальная практика. -М.: НОРМА, 2000 |
| 71 | Переводчиков Н.И. обеспечение качества жизни больных в процессе противоопухолевой химиотерапии (лекция) // Тер. Архив. - 1996 - Т10 - с. 37-41. |
| 72 | Перегудов С.П., Лапина Н.Ю., Семененко И.С. Группы интересов и российское государство. - М.: Эдиториал УРСС, 1999 |
| 73 | Профилактика через первичное здравоохраниние. Рекомендации ВОЗ для улучшения качества работы СИНДИ ЕРБ ВОЗ, копенгаген - 1995. |
| 74 | Распопова С.С. Журналистское творчество: теория и практика освоения: Монография. - М.: МАКС Пресс, 2006 |
| 75 | Реснянская Л.Л. Двусторонняя коммуникация: методика организации общественного диалога. - М.: Пульс, 2000 |
| 76 | Римашевская Н.М. Человек и реформы: секреты выживания. - М.: ИСЭПН РАН, 2003 |
| 77 | Руководство по психиатрии. Под ред.АВ.Снежневского. В 2-х т. М/1983. |
| 78 | Рывкина Р.В. Драма перемен. - М.: Дело, 2001 |
| 79 | Рывкина Р.В. Социология российских реформ: социальные последствия экономических перемен: Курс лекций. - М.: Издательский дом ГУ-ВШЭ, 2004 |
| 80 | Рэндалл Д. Универсальный журналист. - М., 1996 |
| 81 | Савин А.А., Шихкеримов Р. К., Вель-шер Л.З. и др. Психоэмоциональные нарушения и их коррекция у больных, перенесших радикальное лечение по поводу рака молочной железы, www.aswomed.ru |
| 82 | Самарцев О. Р. Творческая деятельность журналиста - М.: Академический проект, 2007 |
| 83 | Сенкевич Н.Ю., Белевский А.С. Качество жизни - предмет научных исследований в пульманологии// Тер. Архив - 2000 - Т3 - С. 36-41. |
| 84 | Сквирская Г.П. Профилактика заболеваний и укрепления здоровья населения// Здравоохранение - 2000 - №11 - С. 11-13. |
| 85 | Смелзер Н. Социология: Пер. с англ. - М.: Феникс, 1994 |
| 86 | Смирнов С.Н., Сидорина Т.Ю. Социальная политика: Учебное пособие. - М.: Издательский дом ГУ-ВШЭ, 2004 |
| 87 | Солганик Г.Я. Стиль репортажа. - М.: изд-во Московского университета, 1970 |
| 88 | Социальная журналистика: профессия и позиция. - М.: АСИ, 2005 |
| 89 | Социальная политика в современной России: реформы и повседневность/Под ред. П. Романова и Е. Ярской-Смирновой. - М.: ООО "Вариант", ЦСПГИ, 2008 |
| 90 | Социальная политика. Энциклопедия/Под ред. Н.А. Волгина, Т.С. Сулимовой. - М.: Альфа-Пресс, 2006 |
| 91 | Социальная политика/Под общ. ред. Н.А. Волгина. - 4-е изд., перераб. и доп. - М.: Экзамен, 2008 |
| 92 | Социальное: истоки, структурные профили, современные вызовы/ Под общ. ред. П.К. Гречко, Е.М. Курмелевой. - М.: Российская политическая энциклопедия (РОССПЭН), 2009 |
| 93 | Социальные инициативы российских СМИ. - М.: АСИ, 2004 |
| 94 | Стародубов В.И. Проблемы Российской Смертности, её последствия и приоритетные направления действий / В.И. Стародубов, Ю.В. Михайлова, А.Е. Иванова// Преждевременная и предотвратимая смертность в России - критерий потери здоровья населения : сб. тр. Всерос. науч. - практ. конф. - М. - 2006 - с. 4-41. |
| 95 | Стародубов В.И. Соболева Н.П. стратегия профилактики заболеваний в условиях реформирования здравоохранения // Экономика здр. - 2002 - №1 - с. 5-10. |
| 96 | Тадевосян Э.В. Социология: Учебное пособие/Под общ. ред. проф. Э.В. Тадевося-на.-М.: Знание, 1995 |
| 97 | Тертычный А.А. Жанры периодической печати: Учебное пособие. -М.: Аспект Пресс, 2000 |
| 98 | Тертычный А.А. Логическая культура журналиста: Учебное пособие для вузов. - М.: ВК, 2005 |
| 99 | Тертычный А.А. Расследовательская журналистика: Учебное пособие для вузов. - М.: Аспект Пресс, 2002 |
| 100 | Тертычный А.А. Социальное познание в журналистике. - М.: МГУ, 2008 |
| 101 | Фихтелиус Э. Десять заповедей журналиста, пер. со шведск. - Швеция, Кальмар: FOJO, 2003 |
| 102 | Франкл В. Человек в поисках смысла. - М.: Прогресс, 1990 |
| 103 | Фролова Т.И. Динамика стратегий в социальном медиадискурсе// "Вестник Московского университета", серия 10 "Журналистика", 2009, №6 |
| 104 | Фролова Т.И. Мужские медиаобразы с лица и с изнанки//Журна-лист. - 2009. - 8 |
| 105 | Фролова Т.И. Опыт дистанционного обучения в профессиональном образовании журналистов//Современная российская периодика: теория и исследования. - М.: Икар, 2007 |
| 106 | Фролова Т.И. Предметно-тематическая специализация в системе профессионального образования журналистов//"Вестник Московского университета", серия 10 "Журналистика, 2007, № 6 |
| 107 | Фролова Т.И. Социальные приоритеты в коммуникативных стратегиях российских СМИ//"Вестник Московского университета", серия 10 "Журналистика", 2005, № 2 |
| 108 | Хожаев А.А. Исследование трудоспособности и качества жизни больных раком ободочной кишки на амбулаторном этапе наблюдения// Тер. Вестник - 2008 - №1(17) - с.44-45 |
| 109 | Хожаев А.А. Оценка качества жизни больных раком прямой кишки //Вест.межнац. Центра исслед качества жизни - 2008 - №11-12 - с. 70-76. |
| 110 | Ципори Д. Роль факторов стромалъных клеток (рестрикти-нов) в микроорганизации кроветворной ткани. Пробл. гематол. 1996; 1:55-7- |
| 111 | Чиссов В.И. Заболеваемость злокачественными новообразованиями в России в 2007 году (заболеваемость и смертность) под ред. В.И. Чистова, В.В. Старинского - М: ФГУ "МНИОЙ им. П.А. Герцена Росмедтезнологий, -2009. - 244с. |
| 112 | Чиссов В.И. Злокачественные новообразования в России В 2009 г. Под редакцией В.И.Чиссова…… Москва 2011 |
| 113 | Чиссов В.И. Состояние онкологической помощи населению России в 2007 г. // Под ред. В. И. Чиссова и др. — М., 2008. |
| 114 | Шевченко Ю.А. Качество жизни в радиологии// Вестник РВМА - 2000 - Т9 - С. 5-15. |
| 115 | Шиган Е.Н. Системный анализ в здравоохранении. - Учебное пособие. М.: ЦОЛИУВ., 1982 - 72с. |
| 116 | Шишкин С. Экономика социальной сферы. - М.: ГУ-ВШЭ, 2003 |
| 117 | Шостак М.И. Репортер: профессионализм и этика. - М.: РИП-хол-динг, 2001 |
| 118 | Штомпка П. Социология. Анализ современного общества/Пер, с польск. - М.: Логос, 2008 |
| 119 | Щепин О.П., Овчаров В.К., Нечаев В.С. Доступность профилактической помощи для лиц, составляющих группу риска // Проблемы соц., здр. И истории мед. - 2000 - №2 - С. 3-12. |
| 120 | Эрхард Л. Благосостояние для всех. - М.: Начала-Пресс, 1991 |
| 121 | Ярская-Смирнова Е. Р, Романов П.В. Социальная антропология. -М.: Социальная защита, 2004 |
| 122 | Aaronson N.K., BuUinger M.(ia! approach to quality of life assessment in cancer cH;:tcai lr;ais // Recent Results Cancer Res. - 1988. - Vol. III. ~ P. 231-241. |
| 123 | Abe T, Makimoto Д Kawano Y el al. Intra-apheresis recruitment of blood progenitor cells in children. Transfusion 1998; 38 (10): 944-50. |
| 124 | Abramsson A, Berlin O, Papayan H et al Analysis of mural cell recruitment to tumor vessels. Circulation 2002; 105 (1): 112-7. |
| 125 | Agaram N.P, WongG.C.Novel V600E mutationes in imatinib-naïve- resistent GIST.Genes Chromosomes Cancer,2008,v.47,p/853-859. |
| 126 | Ahn S.J., Yoon M.S., Hyuk S. etal. Phospholipase C=protein kinase C mediated phospholipase D activation pathway is involved In tamoxifen induced apoptosis. J Cell Biochem 2003;89(3):520-8. |
| 127 | AiutiA, Webb IJ, Bleu! С et al. The chemokine SDF-1 is a chemoattrac-tanl for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of'CD(34+'progenitors tope-ripheral blood. J Exp Med 1997; 185:111-20. |
| 128 | Amaravadi R.K., Yu D., Lum J.J. etal. Autophagy Inhibition enhances therapy-Induced apoptosis In a Myc-Induced model of lymphoma. J Clin Invest 2007;! 17(2):326-36. |
| 129 | Amaravadi R.K., Yu D., Lum J.J. etal. Autophagy Inhibition enhances therapy-Induced apoptosis In a Myc-Induced model of lymphoma. J Clin Invest 2007;! 17(2):326-36. |
| 130 | American Cancer Society: Cancer Facts and Figures 2008 // - Athnta Qa: American Cancer Society, 2008 |
| 131 | Ancoli-Israel S, Liu L, Mailer MR el al Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 2006; 14(3): 201-9. |
| 132 | Anders C.K., Carey L.A. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009;2:73-81. |
| 133 | Andrykowski MA, Curran SLJJgbtnerR. Off-treatment fatigue in breast cancer survivors: a controlled comparison.]'Behav Med 1998; 21:1-18. |
| 134 | Anthony RS, McKelvie ND, Cunningham AJ et al Flow cytometry using annexin V can detect early apoplosis in peripheral blood stem cell harvests from patients with leukaemia and lymphoma. Bone Marrotv Transplant 1998; 21 (5): 441 -6. |
| 135 | ArdizzoiniA,Hansen Д Dombernowsky P etal, Topotecan, a new active drug in the second line treatment of small-cell lung cancer: a phase II study in patients with refractory^ and sensitive disease.} Clin Oncol 1997; 15:2090-6. |
| 136 | Assessment of Quality of Life in Childhood Asthma / Eds M. Christie, D. French. - Switzerland: Harwood Academic Publishers, 1994. -P. 99-106. |
| 137 | AUIU, Campbell G, Lidereau R, CallabanR. Amplification ofc-erbB-2 and aggressive human breast tumors? Science 1983; 240 (4860): 1795-6. |
| 138 | Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005; 15 (11): 102-11. |
| 139 | Baluk P, Lee CG, Link H et al. Regulated angiogenesis and vascular regression in mice overexpressing vascular endotbelial growth factor in airways. Am J Pathol 2004; 165 (4): 1071-35. |
| 140 | Banks WA. Cytokines, CVs, and the blood-brain barrier, in Psychoneu-roimmunology, 3rd Edition, Ed. byAderR., Felton DL, When N. San Diego, CA: Academic Press, 2001:483-99. |
| 141 | Basham V, Lipscombe J., Word J. et al. BRCA 1 and BRCA 2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002;4:1-5. |
| 142 | BeadlingC.KITgene mutationes and copy number in GIST.Clin.Can/Res 2008,v.14,p.6821-6828 |
| 143 | Beck A., Steer R., Garb in M. Psychometric properties of the Beck Depression Inventory: twenty-five years of evaluation // Clin. Psychol. Rev. - 1988. - No. 8. - P. 77-100. |
| 144 | Benjamin LE, KeshetE. Conditional switching of vascular endothelialgroivth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma4ike vessels by VEGF 'Withdrawal. ProcNatlAcadSd USA 1997; 94 (16): 8761-6. |
| 145 | Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. \at Rei' Cancer'2003; 3 (6): 401 -10. |
| 146 | Bergner M., Bobbin R., Kressel $. et al The Sickness Impact Profile: conceptual formulation and methodology for the development of a health status measure // Int. J. Health Serv. - 1976. - No. 6. - P. 393-415. |
| 147 | Berry DA., Cronin K.A., Plevritis S.K. et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92. |
| 148 | Besedovsky H, del Rey A, Sorkin E et al. Immunoregulatory feedback between interleukin-1 and glucocorlicoid hormones. Science 1986; 233 (4764): 652-4. |
| 149 | Bilir A., Altinoz M.A., M. etal. Autophagy and nuclear changes In FM3A breast tumor cells after epirubicin, medroxyprogesterone and tamoxifen treatment in vitro. Pathobiology 2061;69(3):120-6. |
| 150 | Bilir A., Altinoz M.A., M. etal. Autophagy and nuclear changes In FM3A breast tumor cells after epirubicin, medroxyprogesterone and tamoxifen treatment in vitro. Pathobiology 2061;69(3):120-6. |
| 151 | Biumberg M. S. Evaluation heaith screening procedures // Operat. Res.- 1954.- Vol. 5, N3.- P. 351-360. |
| 152 | Borgstrom P, Gold DP, Hillan et al Importance ofVEGFfor breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monddonal antibody anddoxoru-bicin. Anticancer Res 1999; 19 (5B): 4203-14. |
| 153 | Boyle P. Epidemiology of colorectal Cancer / P/ Boyle, M.E. Yeon// Brit. Med. Bull. - 2002 - Vol 64 - P1 - 25 |
| 154 | Bradley C., Gamsu D.S. Guidelines for encouraging psychological well-being: report of a Working Group of the World Health Organization Regional Office for Europe and International Diabetes Federation European Region St Vincent Declaration Action Programme for Diabetes // Diabet. Med. - 1994. - Vol. 11, No. 5. - P. 510-516. |
| 155 | Brose M.S., RebbeckT.R., Calzone K.A. et al. Cancer risk estimates for BRCA 1 mutation carriers indetifiend in a risk evaluation program. J National Cancer Inst 2002;94(18):1365-72. |
| 156 | Brown JM. Tumor microem wonment and the response to anticancer therapy. Cancer Biol Tber 2002; 1 (5): 453 -8. |
| 157 | Bruera E, Valero V. Driver L et al. Patient-controlled metbylpbenidate for cancer fatigue: a double-blind, randomized., placebo-controlled trial. У Clin Oncol2006; 24 (13): 2073-8. |
| 158 | Bruil J., Maes S., Cog L. et al. The development of the How Are You? (HAY), a quality of life questionnaire for children with a chronic illness // Qual. Life Newslett. - 1997. - No. 18. - P. 9. |
| 159 | Buisch W, Ellinger A., H. etal. Active cell death Induced by the anti-estrogens tamoxifen and ICI 164 384 In human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis 1996; 17(8): 1595^-607. |
| 160 | Bullinger M., Ravens-Sieberer U. Assessing health-related quality of life in chronically ill children with the German KINDL: first psychometric and content analytical results // Qual. Life Res. - 1998. - Vol. 7, No. 5. - P. 399-407. |
| 161 | Burckhardt C.S., Clark S.R., Bennett R.M. The Fibromyalgia Impact Questionnaire: development and validation // J. Rheumatol. - 1991. -Vol. 18. - P. 728-733. |
| 162 | Bursch W., Hochegger K., Torok L. etal. Autophagic and apoptotic types of programmed cell death exhibit different fates of cytoskeletal filaments. J Cell Sci 2000;! 13 (7):1189-98. |
| 163 | Butta A., MacLennan K., Flanders K.C. etal. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992;52(15):4261-4. |
| 164 | Caceres W, Gonzalez S. Angiogenesis and cancer: recent advances. P R Health Sci J 2003; 22(2): 149-51. |
| 165 | Capuron L GumnickJF. Mussehnan DL et al. Neurobebavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002; 26: 643-52. |
| 166 | Capuron LRavaud A, DantzerR. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med 2 001; 63:3 76-86. |
| 167 | Carlson TR, Van Y^ruX etal Endothelial expression ofconstitutively active Notch4 elicits reversible anenovenous malformations in adult mice. Proc NatlAcad Sci USA 2005; 102 (28): 9884-9. |
| 168 | Carmeliet PJain RK.A}igiogenesis In cancer and other diseases. Nature 2000; 407 (6801): 249-57. |
| 169 | Casali p.g,Blay j.y.GIST-ESMO Clinical practice guidelans for diagnosis.Annals of Oncology 2010,sup.5,p.98-102 |
| 170 | Cascinu S, Graziano F, Ferrau F et al. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas"(GISCAD).Ann Oncol2002; 13: 7'16-20. |
| 171 | CassidyJ, Tivelves C, van Cutsem E et al. First line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5 fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-75. |
| 172 | Cella D, Davis K, Brettbart Wet al. Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of'cancer survivors.} Clin Oncol 2001; 19:3385-9L |
| 173 | Cella D, PetermanA, S et al Progress toward guidelines for the management of fatigue. Oncology 1998; 12:369-77- |
| 174 | Cella Д LaiJS, Chang CTI et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002; 94: 528-38. |
| 175 | Chan S, Fnedncbs K, Noel D et at Prospective randomized trial of do-cetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999; 17:2341 -54. |
| 176 | Chaplin J.E., Yepez R., Shorvon S. et. al. A quantitative approach to measuring the social effects of .epilepsy // Neuroepidemiology. - 1990. -Vol. 9. - P. 151-158. |
| 177 | ChaudhuriA, Behan PO. Fatigue and basal ganglia. JNeurol Set 2000; 179 (SuppL 1-2): 34-42. |
| 178 | Chen T.C., Su S., Fry D., Llebes L. Combination therapy with irinotecan and protein kinase C Inhibitors in malignant glioma. Cancer 2003;97(9):2363-73. |
| 179 | Chen Y.M., R.P., Yang K.Y. etal. Combination chemotherapy with tamoxifen, Ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer. Zhonghua Yi Xue Za Zhi (Taipei) 2000;63(8):605-11. |
| 180 | Cheng A.L, Chuaeg S.E., Fine R.L. etal. Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxomblcin-Induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol 1998;55(4):523-31. |
| 181 | Chu D., Lu J. Novel therapies in breast cancer: what is new from ASCO 2008. J Hematol Oncol 2008. |
| 182 | Cjrless C,Heinrih V.C.Molecular pathobiology of GIST.Ann.Res.Pathol.2008,v.3,p.557-586. |
| 183 | Cobleigh MA, Langmuir VK, Sledge GW et al.A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30 (Suppl 16): 117-24. |
| 184 | Coussens L, Yang-Feng TL, Liao YC et al Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985; 230 (4730): 1132-9. |
| 185 | Creemers G}} Bolls G, Gore M et al. Topotecan, an active in the second line treatment of epithelial ovarian cancer: results of a large European phase II study.] Clin Oncol^ 1996; 14:3056-61. |
| 186 | CullumJL, Wojciechowski AE, Pettetier G et al. Bupropion sustained-release treatment reduces fatigue in cancer patients. Can J Psychiatry 2004; 49:139-44* |
| 187 | Cutter C,AntinJH. Peripheral blood stem cells for allogenic transplantation: a review. Stem Cells 2001; 19:108-17. |
| 188 | Cytokine responses of hematopoietic progenitor cell, ISH-EHA 1999: 51-5. |
| 189 | Day T.W., S., Safa A.R. c-FLIP knockdown Induces ligand-independent DR5-, FADD-, caspase-8-, and caspase-9-dependent apoptosis in breast cancer cells. Biochem Pharmacol 2008;76(12):1694-704. |
| 190 | Day T.W., Sinn A.L. c-FLIPgene silencing eliminates tumor cells in breast cancer xenografts without affecting stromal cells. Anticancer Res 2009;29(10):3883-6. |
| 191 | De LIgio J.T., Velkova A., Zorlo D.A. etal. Can the status of the Breast and Ovarian Cancer Susceptibility Gene 1 product (BRCA 1) predict response to taxane-based cancer therapy? Anticancer Agents Med Chem 2009;543-9. |
| 192 | DelucaJ. Fatigue, cognition, andmental effort, in Fatigue as a Window to the Brain. Ed. by DeLucaJ. Cambridge, MA, MIT Press, 2005:3 7-58. |
| 193 | DiLauro L, Belli F. Arena MG et al Epinibicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. Ann Oncol2005,16:1498-502. |
| 194 | Dimeo FC, StieglitzRD, Novelli-Fiscber U et al. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer 1999; 85; 2273-7. |
| 195 | Dixon T., Lim L.L., Oldridge N.B. The MacNew heart disease health-related quality of life instrument: reference data for users // Qual. Life Res. - 2002. - Vol. 11, No. 2. - P. 173-183. |
| 196 | Dodrill C.B. A neuropsychological battery for epilepsy // Epilepsia. -1978. -Vol. 19. - P. 611-623. |
| 197 | Donna D. Evolutionary considerations in hematopoietic develop-ment.AnnN-YAS 1999:84-9 L |
| 198 | Donovan KAJacobsen PB,AndrykowskiMA et al. Course of fatigue in women receiving chemotherapy and/or radiotherapy for early-stage breast cancerJ Pain Symptom Manage 2004; 28:373-80. |
| 199 | Dow KH, FerrettBR, Leigh S et al.An evaluation of quality of life among long-term survivors of breast cancer. Breast Cancer Res. Treat 1996; 39: 261-73. |
| 200 | Doward L., SpoorenbergA., Cook S. et al. Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis // Ann. Rheum. Dis. - 2003. - Vol. 62. - P. 20-26. |
| 201 | Ebihara Y, Xu MJ, ManabeA el al. Exclusive expression ofG-CSF receptor on myeloid progenitors in bone marrow CD34+cells. BrJ Haemalol 2000; 109: 153-61. |
| 202 | Esteller M. Epigenetics in cancer. N Engl ] Med 2008; 358 (11): 1148^59. |
| 203 | Esteva FJ, Valero V, BooserD et al Phase II study of weekly docetaxel and trastuzumab for patients with HER-2 overexpressing metastatic breast cancer.J Clin Oncol 2002; 20:1800-8. |
| 204 | Eypasch E., Williams J.I., Wood-Dauphinee S. et al. Gastrointestinal Quality of Life Index: development, validation and application of a new instrument // Br. J. Surg. - 1995. - Vol. 82, No. 2. - P. 216-222. |
| 205 | Fabian MR, Sonenberg N, Filipowicz W. Regulation ofmRNA translation and stability by microRNAs.Annu Rev Biochem 2010; 79:351- 79. |
| 206 | Fandy T.E., Shankar S., Srivastava R.K. Smac/DIABLO enhances the therapeutic potential of chemotherapeutic drugs and irradiation, and sensitizes TRAIL-resistant breast cancer cells. Mol Cancer 2008;7:60-9. |
| 207 | Ferrara N. GerberHP, LeCouterJ. The biology? ofVEGF and its receptors. NatMed 2003; 9 (6): 669-76. |
| 208 | FetraraN, Davis-Smyth T. The biology of vascular endothelialgroivth factor. EndocrRev 1997; 18 (1): 4-25. |
| 209 | Fischer J.S., LaRocca N.G, Miller D.M. et. al. Recent developments in assessment of quality of life in multiple sclerosis // Mult. Scler. -1999. -Vol. 5, No. 4. - P. 251-259. |
| 210 | Fleishman S, Lower E, ZeldisJ et al A phase II, randomized, placebo-controlled trial of the safety1 and effi cacy ofdexmethylphenidate (d-MPH) as a treatment for fatigue and "chemobrain" in adult cancer patients. Breast Cancer Res Treat 2 005; 94:5214. |
| 211 | Folkman J. Tumor angiogenesis: therapeutic implications.NEnglJMed 1971; 285 (21):1182-6. |
| 212 | FolkmanJ,Role of angiogenesis in tumour growth and metastasis, Semin Oncol 2002; 29 (Suppl 16): 15-8. |
| 213 | Foster F.M., Owens T.W., Tanianis-Hughes J. etal. Targeting inhibitor of apoptosis prdteins in combination with ErbB antagonists In breast cancer. Breast Cancer Res 2009; 11 (3): 1-13. |
| 214 | Frank T.S., Deftenbaugh A.M., Reid J.E. et al. Clinical characteristics of individuals with germinel mutations in BRCA 1 and BRCA 2: analysis of 10,000 individuals. J Clin Oncol 2002;20(6): 1480-90. |
| 215 | Fries J., Spitz P., Young D. The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales // J. Rheumatol. - 1982. - Vol. 9. - P. 789-793. |
| 216 | Frogne T., Jepsen J.S., Larsen S.S. etal. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr Relat Cancer 2005;12(3):599-614. |
| 217 | FruehaufS, VeldwijkMR, Kramer A et al. Delineation of cell cycle state and correlation to adhesion molecule expression of human CD34+ cells from steady-state bone marrow and peripheral blood mobilized following G-CSF-supported chemotherapy. Stem Cells 1998; 16 (4): 271 -9, |
| 218 | Fu Y.M., Li Q.M., Zhang .CY. etal. of 40H-tamoxifen on the proliferation and apoptosis of prostate stromal cells. Zhonghua Nan KeXue 2007;13(7):620-™3. |
| 219 | G, Ramaknsbnan G, Sekbar Rao С et al. Reduced cardiotoxicity and preserved antitumor efficacy of tiposome-encapsulated doxorubicin and cydopbospbamide compared with conventional doxorubicin and cydopbospbamide in a randomized, multicenter trial of metastatic breast cancer.J Clin Oncol 2001; 19: 1444-54. |
| 220 | Gabrilovicb DI, Chen HL, GirgisKR et al Production of vascular endothelial groivth factor by) human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2 (10): 1096-103. |
| 221 | Gagliardi A.R., B., Collins D.C. Antlestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors. Anticancer Res 1996; 16(3): 1101-6. |
| 222 | Garvin S., Dabrosin C. Tamoxifen Inhibits secretion of vascular endothelial growth factor In breast cancer in vivo. Cancer Res2003;63:8742-8. |
| 223 | Garvin S., Dabrosin C. Tamoxifen Inhibits secretion of vascular endothelial Role of mitochondria In tamoxlfen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 2005;10(6):1395-410. |
| 224 | Gaston-Johansson F. Fatt-Dickson JM} BakosAB et al. Fatigue, pain, and depression in pre-autotransplant breast cancer patients. Cancer Practl999;7:240-7. |
| 225 | Gatzemeier U, von PawelJ, Gottfried M et al Phase III comparative study of high dose cisplatin versus a combination of cisplatin and pacli-taxel in patients with advanced поп small cell lung cancer.] Clin Oncol 2000; 18:3390-9. |
| 226 | Gayther S.A., Kurosaki T. et al. Mutation analysis of BRCA 1 and BRCA 2 in a male breast cancer population. Am J Human Genet 1997;60(2):313-9. |
| 227 | Georgulias V, Papadakis E, Alexopulos A et al. Platinum-based and nonplatinum-based chemotherapy in advanced non-small cell lung cancer: a randomized multicentre trial Lancet 2001; 357:1478-84. |
| 228 | GerberHP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bd~2 andAl in vascular endothelial cells.} Biol Cham 1998;273 (21): 13313-6. |
| 229 | GerberHP, McMurtreyA, KoivalskiJ et al Vascular endotbelial groitb factor regulates endotbelial cettsuhnval through the phosphatidylinositol 3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation, JBiol Chem 1998; 273 (46):30336-43. |
| 230 | Gil T,Schoffski P.Final analysis of Phase I single-dose-escalation study . BI6727 in pat. With advanced solid tumors.J Clin Oncol 2010,v.28,15p. |
| 231 | Glaspy J. Anemia and fatigue in cancer patients. Cancer 2001; 92 (Suppl 6): 1719-24. |
| 232 | Gndelli C, Perrone F, Gatto С et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. EurJ Cancer 1997; 33:392-7-34* Hainsworth JD, Gray JR, Stroup SL et al Paclitaxel, carboplatin and extended schedule etoposide in the treatment of small cell lung cancer: comparison of sequential phase II trials using different dose intensities.} Clin Oncol 1997; 1.5:3464-70. |
| 233 | Gordon AN, Granai CO, Rose PG et al. Phase II study ofUposomal oxo-rubicin in platinum andpaclitaxel refractory epithelial ovarian cancer.] Clin Oncol2000; 18:3093-ЮО. |
| 234 | Gordon MS, Margolin K, TalpazM et al. Phase I safety and pbarmacokinetic study ofrecombinant human anti-vascular endothelial growth factor in patients with advanced cancer.] Clin Oncol 2001; 19 (3): 843-50. |
| 235 | Gramza A.W,Corless C.I.resistance of tyrosine Kinase Inhibitions of GIST .Clin Canc res 2009,v.15,p.7510-7518 |
| 236 | Gramza A.W,heinrich M.C.Optimizing the treatment of GIST.ASCO 2010,educational book,p.454-460. |
| 237 | Guillemin F., Coste J., Pouchot J. et al. The AIMS2-SF. A Short Form of the Arthritis Impact Measurement Scales 2 // Arthritis Rheum. -1997. - Vol. 40, No. 7. - P. 1267-1274. |
| 238 | Gustafsson A., Martuszewska D., Johansson M. etal. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res 2009; 15:4742-9. |
| 239 | Gyger M, Stuart RK, Perreault C. Immunology of attogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. Bone Marrow Transplant 2000; 26: 1-16. |
| 240 | Haas R, Mohle R, Pforsicb M et al. Blood-derived autografts collected during granulocyte colony-stimulating factor-enhanced recovery* are enriched with early Thy-l+ hematopoieticprogenitor cells. Blood 1995; 85: 1936-43. |
| 241 | Hanahan D, FolkmanJ. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86 (3): 353 -64. |
| 242 | Hann DM, Denniston MM, Baker F. Measurement of fatigue in cancer patients: Further validation of the Fatigue Symptom Inventory. Qua! Life Res2000; 9: 847-54. |
| 243 | Hann DMJacobsen PB, Martin S et al. Fatigue and quality of life following radiotherapy for breast cancer: a comparative study.} Clin Psychol Med Set 1998; 5:~19-33. |
| 244 | Hardt P.D,Ngoumou B,Rupp B. Anticancer Res- 2003. - Уо1. 23. - Р. 851—854. |
| 245 | Hardt P.D,Ngoumou B,Rupp B. Anticancer Res- 2003. - Уо1. 23. - Р. 851—854. |
| 246 | Hawkins R, Cunningham D, Soerbye H et al. Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil in patients with untreated advanced gastric adenocarcinoma. Program and abstracts of the 39tb Annual Meeting of the American Society of Clinical Oncology; May 31 -June 3,2003; Chicago, Illinois. Abstract 1032. |
| 247 | Hicklin D], Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23 (5): 1011 -27. 4LBrasch R, Pham C, Shames D et al Assessing tumor angiogenesis using macro-molecular MR imaging contrast media.]' Magn Reson Imaging 1997; 7 (!)o' 8-74. |
| 248 | Higa GM, DeVore Rf]AuberML et al Biological and clinical correlates after chemotherapy and granulocyte colony stimulating factor administration. Pharmacotherapy 1998; 18 (1): 1-8. |
| 249 | Higgins B. Kolinsky K, Zhang Y-E et al Antitumor activity of a combined regimen of capecitabine and bevacizumab in a xenografl model of human breast cancer. Poster presented at the 2 006 SABCS meeting, San Antonio, Texas, USA. |
| 250 | Hobday T.J., Perez E.A. Molecularly targeted therapies for breast cancer. Cancer Control 2005;12(2):73-81. |
| 251 | Hoepfner N,Shastri Y.M,Hanish E.Aliment/Pharm. - 2006. - Уо1. 23. - Р. 145-154. |
| 252 | Hoepfner N,Shastri Y.M,Hanish E.Aliment/Pharm. - 2006. - Уо1. 23. - Р. 145-154. |
| 253 | Hotta T, Tanlmura H., Yamaue H. Tamoxifen circumvents the multidrug resistance in fresh human gastrointestinal cancer cells. J Surg Res 1996;66(l):31-5. |
| 254 | Hudelist G, Kostler WJ, Czerwenka К et al. Her-2/neu andEGFR tyrosi-tie kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer. IntJ Cancer 2006; 118 (5): 1126-34- |
| 255 | Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N EnglJ Med 200 7; 35 7 (1): 39-51. |
| 256 | Hunter A.M., LaCasse E.C., Korneluk R.G. The Inhibitors of apoptosis (lAPs) as cancer targets. Apoptosis 2007; 12:1543-68. |
| 257 | Imyanitov EN, Chernitsa OI, Serova OM et al. Amplification of HER-2(erbB~2/neu) oncogene as the most significant prognostic factor in a group of Russian breast cancer patients. Neoplasma 1993; 40 (1): 35-9. S.Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al FinHer Study Investigators. Adjuvant docetaxel or linoretbine with or without trastuzumab for breast cancer. NEngl'JMed 2'006:354 (8): 809-20. |
| 258 | Inai T, Mancuso Al Hashizume II el al Inhibition oft 'oscular endothelial gt ouib factor (VEGF) signaling in cancer causes loss of endotbelialfenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am] Palhol 2004; 165(1): 35-52. |
| 259 | Irvine E.J. Quality of Life-rationale and methods for developing a disease-specific instrument for inflammatory bowel disease // Scand. J. Gastroenterol. - 1993. - Suppl. 199. - P. 22-27. |
| 260 | Isaac Y.K., Byung-Chul K., Do Hwan S. etal. Raloxifene, a mixed estrogen agonist/ antagonist, induces apoptosis In androgen-independent human prostate cancer cell lines. Cancer Res 2002;62:5365™9. |
| 261 | Jacobsen PB, Hann DM. Azzarello LM et al. Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates.}Pain Symptom Manage 1999:18:233-*/2. |
| 262 | Jacobsen PB, Slein K. Is fatigue a long-term side effect of breast cancer treatment? Cancer Control 1999:6:256-63. |
| 263 | Jain RK, Safabakbsb N, SckellA et al Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen -dependent tumor: role of vascular endothelial groivth factor. Proc NatlAcadSci USA 1998; 95 (13): 10820-25. |
| 264 | Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9 (6): 685-93. |
| 265 | Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new'paradigm for combination therapy. NatMed2001; 7 (9): 987-9. |
| 266 | JainRK. Normalization of tumor vasculature: an emerging concept in antiangio-genie therapy. Science 2005; 307 (5706): 58-62. |
| 267 | Jensen E.V., Jordan V.C. The estrogen receptor: a model for molecular medicine. Clin Cancer Res 2003;9:1980. |
| 268 | Joensuu h,Roberts P.I,Anderson L.C. Effect of the tyrosine kinase inhibitor STI57l in a pacient with a metastatic GIST.N.Engl.J.Med/2001,v.344.p.1052-1056 |
| 269 | Joensuu H.GIST therapy and treating the first patient with imatinib.Helsinki 1-3 oct,2010 |
| 270 | Jones P.W., Quirk F.H., Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire // Am. Rev. Respir. Dis. - 1992. - Vol. 145, No. 6. - P. 1321-1327. |
| 271 | Jones S, Winer E. \ oget С et al. Randomized comparison of vinorelbine and melphalan in antbracy dine-refractory advanced breast cancer. J Clin Oncol 1995; 13:256"-"4- |
| 272 | Jordan V.C. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 2008;44(l):30-8. |
| 273 | Juniper E., Guyatt G., Feeny D. Measuring quality of life in children with asthma // Qual. Life Res. - 1996. - Vol. 5. - P. 35-46. |
| 274 | Juniper E.F., Guyatt G.H., Feeny D.H. et al. Minimum skills required by children to complete health-related quality of life instruments for asthma: comparison of measurement properties // Eur. Respir. J. - 1997. - Vol. 10, No. 10. - P. 2285-2294. |
| 275 | Kallio A., Zheng A., Dahllund J. etal. Role of mitochondria In tamoxlfen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 2005;10(6):1395-410. |
| 276 | Kamba T, Tarn BY. Hashizume H et al VEGF-dependent plasticity offenestrat-ed capillaries in the normal adult microvasculature. Am JPhysiol Heart Circulatory Physiol2006; 290 (2):H560-76. |
| 277 | Kaplan R., Bush J., Berry C. Health status: types of validity and the Index of Well-being // Health Serv. Res. - 1976. - Vol. 11. - P. 478-507. |
| 278 | Kiel K, Cremer FW, Ebrbrecbl E et al. First and second apberesis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield. Bone Marrow Transplant 1998; 21 (11): 1109-15. |
| 279 | Kim KJ, LiB,WinerJ et al Inhibition of vascular endothelial groivth factor-induced angiogenesis suppresses tumour groivth in vivo. Nature 1993; 362 (6423): 841-4. |
| 280 | Kindwall-Keller TL Otterson GA, Young D el al. Phase II evaluation of docetaxel and capecitabine in previously treated non-small cell lung cancer patients. Program and abstracts of the 39lb Annual Meeting of the American Society of Clinical Oncologi*: May 31-June 3- 2003: Chicago, Illinois. Abstract 2601. |
| 281 | Kirsh KL Passik S, Iloltsdair E et all get tired for no reason: a single-item screening for cancer-related fatigue. JPain Symptom Manage 2001: 22:931-3^. |
| 282 | Konecny G, Pauletti G, Pegram M el al. Ouantitatit r association betive-enHER-2/neu and steroid hormone i eceptors in hormone receptor-positive primary breast cancer.JXatl Cancer Inst 2003:95 (2): 142-53. |
| 283 | Kosmas С Tsavaris X. Panopulos С et al. Gemcitabine and vinorelbi-ne as second line therapy in поп small cell lung cancer after prior treatment with taxane + platinum based regimens. EurJ Cancer 2001; 3"~: 972-8. |
| 284 | Kovach NL, Lin N, Yednock Т el al. Stem cell factor modulates avidity of a4$i and "5/5/ integrins expressed on hematopoietic cell lines. Blood 1995; 85:159-67. |
| 285 | Kronenwett R, Martin S, Haas R. The Role ofCytokines and Adhesion Molecules for Mobilization of Peripheral Blood Stem Cells. Stem Cells 2000; 18 (5): 320-30. |
| 286 | Kubera M, Holan \ \ Mathison R el al: The effect of re pealed amitnpty-line and desipramine administration on cvtokine release in C5~"BL/() mice.Psychoneuroendocrinology2000:25: "85-9"'. |
| 287 | Kubera M, Maes M, Kenis G et al, Effects of serotonin and serotonergic agonists and antagonists on the production of tumor necrosis factor alpha and interleukin-6. Psychiatry Res 2005; 134:251-8. |
| 288 | L.A., Das S., Clark D.W., Samant R.S. Osteopontin: an effector and. an effect of tumor metastasis. Curr Mol Med 2010;71-81. |
| 289 | Laack E, Mende Г, BenkJ et al. Gemcitabine and vinorelbine as first line chemotherapy for advanced поп small cell lung cancer: a phase II trial EurJ Cancer:2001; 37:583-90. |
| 290 | Lagadec C., Adriaenssens E., Toillon R.A. etal. Tamoxifen and TRAIL synergistically induce apoptosis in breast cancer cells. Oncogene 2008;27( 10): 1472^7. |
| 291 | Lande G, Cook DB, Nalelson EH. Rehabilitation and treatment offati-- gue, in Fatigue as a Window to the Brain. Ed. by Deluca J. Cambridge, MAi MIT Press, 2005:301-16. |
| 292 | LandgrafJ., Abetz L., Ware /. The Child Health Questionnaire (CHQ). A User's Manual. - 2nd printing. - Boston: Health Act, 1999. - 552 p. |
| 293 | LandgraJ J., Abetz L. Measuring health outcomes in pediatric populations: issues in psychometric and application // Quality of Life and Phar-macoeconomics in Clinical Trials. - 2nd ed. / Ed. B. Spilker. - Philadelphia: Lippincott-Raven Publishers, 1996. - P. 793-802. |
| 294 | Langer CJ, LeightonJC, Comis Ж et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis, f Clin Oncol 1995; 13: 1860-70. |
| 295 | Langeveld J. Koot H., Loonen M. et al. A QOL instrument for adolescents with chronic headache // Cephalgia. - 1996. - Vol. 16. - P. 183-196. |
| 296 | Lavie Y, Zhang Z.C., Cao H.T. etal. Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells. Int J Cancer 1998;77(6):928-32. |
| 297 | LeCesne A,Bui B.N.Discontinuation of imatinib in patientswith avanced GIST after 3-y of treatment.Lancer Oncol 2010,v.11,p.942-949 |
| 298 | Lee CG, Heijn M, di Tomaso E et al Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxicor bypoxic conditions. Cancer Res 2000; 60 (19): 5565- 70. |
| 299 | Lee TH,Avraham HKJiang S et al. Vascular endotbelial growth factor modulates the transendothelial migration ofMDA-MB-231 breast cancer cells through regulation of brain microvascular endotbelial cell permeability.] Biol Chem 2003:278 (7): 5277-84. |
| 300 | Leidy N.K., Coughlin C. Psychometric performance of the Asthma Quality of Life Questionnaire in a US sample // Qual. Life Res. - 1998. - Vol. 7, No. 2. - P. 127-134. |
| 301 | LemoliRM, TafuriA, Turn S el al. Cycling Status ofCD34+ Cells Mobilized Into Peripheral Blood of Healthy Donors by Recombinant Human Granulocyte Colony-Stimulating Factor. Bldod 1997; 89 (4): 1189-96. |
| 302 | Leonard BE. The immune system, depression, and the action of anti-depressants (review). Prog Neuropsychophannacol Biol Psychiatry 2001; 25: 767-80. |
| 303 | LeongKG, KarsanA. Recent insights into the role of Notch signaling in tumorigene-sis. Blood 2006; 107 (6): 2223-33. |
| 304 | LevesqueJ-P, Leavesley Dl, Niutta S el al. Cytokines increase human betnopoietic cell adhesiveness by activation of very late antigen (VIA)-4 andWA-5 integrins. J Exp Med 1995; 181:1805-15. |
| 305 | Levy MR. Cancer Fatigue: A Neurobiological Review for Psychiatrists. Psychosomatics 2008; 49:283-9 L |
| 306 | Lewin J.M., D'Orsi C.J., Hendrick R.E. et al. Clinical comparison of full-field digital mammography and screen-film mammography for detection of breast cancer. Am J Roentgenol 2002; 179:671-7. |
| 307 | Lewin J.M., Hendrick R.E., D'Orsi C.J. et al. Comparison of full-field digital mammography with screen-film mammography for cancer detection rates: results of 4,945 paired examinations. Radiology 2001;218:873-80. |
| 308 | LHainaudP, ContreresJO, VillemainA etal. The role of the Vascular Endotbelial Growth Factor-Delta-like 4 Ugand/Notch4-Ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. Cancer Res 2006; 66 (17): 8501-10. |
| 309 | Liu B., Ordonez-Ercan D., Fan Z. etal. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007; 120(9): 1874^82. |
| 310 | Liu ZJ, Shirakatva T. Li Y et al. Regulation of Notch 1 and DU4 by i'oscular endothe - lial growth factor in arterial endotbelial cells: implications for modulating artetiogen- esis and angiogenesis. Mol Cell Biol 2003; 23 (I): 14-25. |
| 311 | LJaneivay CA, Trarers P, Walport M et al. lmmunobiolog\\ 5th ed.Xeic York; Garland Publishing. 2001. |
| 312 | Loge JH, Abrahamsen Al7 et al. Fatigue and psychiatric morbidity among Hodgkin's disease survivors. ] Pain Symptom Manage 2000; 19: 91-9.' |
| 313 | lop A, Manfredi AM, Bonura S. Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol 2004; 15: -712-20. |
| 314 | MacKenzie F. DwiezP,WongF et al. Nolch4 inhibits endotbelial apoptosis via RBP-Jkappadependent and independent pathways. JBiol Chem 2004; 279 (12): 11657-63. |
| 315 | MaianskiNA, MulFP, van BuulJD et al Granulocyte colony-stimulating factor inhibits the mitochondria-dependent activation ofcaspase-3 in neutrophils. Blood2002; 99 (2): 672-9. |
| 316 | Mancuso MR, Davis R, Norberg SM et al. Rapid, vascular regrowth in tumors after reversal ofVEGF inhibition.} Clin Invest 2006; 116(10): 2610-21. |
| 317 | Manificat S.f Dazord A. Children's quality of life assessment: preliminary results obtained with the AUQUEY questionnaire // Qual. Life Newslett. - 1998. - No. 19. - P. 2-3. |
| 318 | Margeli M., Cirauqui B., Castella E. etal. The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. PLoS One 2010;9499. |
| 319 | Markman M, Bundy BN, Alberts DS et al Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and inlraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group. Southwestern Oncology Group and Eastern Cooperative Oncology Group.J Clin Oncol 2001; 19:1001-7. |
| 320 | Marpless M.Sunitinib in GIST.Eur.J Sur Jnc 2008,v.34,p.844-850 |
| 321 | Mazurenco N.N.Analyses prognostic relevance of genetic aberration in GIST. ASCO,2011,abstr.70985. |
| 322 | McEiven BS. Stressed or stressed-out: what is the difference? J Psychiatry Neurosci 2005; 30:315-8. |
| 323 | McGlynn L.M., KirkegaardT., Edwards J. etal. Ras/Raf- 1/MAPK pathway mediates response to tamoxifen but not chemotherapy In breast cancer patients. Clin Cancer Res 2009; 15(4): 1487^95. |
| 324 | McKenna S.P., Doward L.C., Alonso J. et al. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency // Ibid. -.1999. - Vol. 8, No. 4. - P. 373-383. |
| 325 | McManus D.C., Lefebvre C.A., Cherton-Horvat G. etal. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse hemotherapeutics. Oncogene 2004;23:8105-17. |
| 326 | Meenan R., Gertman P., Mason J. et al. The Arthritis Impact Measurement Scales // Arthritis Rheum. - 1982. - Vol. 25, No. 9. -P. 1048-1053. |
| 327 | Miller KD, Chap U, Holmes FA et al Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.] Clin Oncol 2005; 23 (4): 792-9. |
| 328 | Miller KD,Wang M, GralowJ et al.A randomized phase HI trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2 005; 94 (Suppl. 1): S6 [abstract 3]. |
| 329 | MillwardMJ, Bishop JF, Friedlander M et al. Phase II trial of a 3 hour infusion of paclitaxel in previously untreated patients with advanced nonstnall cell lung cancer. J Clin Oncol 1996; 14:142-8. |
| 330 | Minton O, Richardson A, Sharpe M et al.A systematic review and me-fa-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008; 100:1155-66. |
| 331 | Mohamad H., Apffelstaedt J. Counseling for male BRCA mutation carriers - a review. Science Direct 2008:1-10. |
| 332 | Mohle R, BautzF, Rafii S et al. Regulation of Transendothelial Migration of Hematopoietic Progenitor Cells. Ann N-YAS. 1999; 872:176-86. |
| 333 | Mohle R, Moore MA, Nachman Ж et al. Transendolhelial migration of CD34+ and mature hematopoietic cells: an in vitro study using a human bone marrow endothelial cell line. Blood 199 7; 89: 72 -80. |
| 334 | Mohle R, Murea S, Kirsch M et al. Differential expression of'L-selectin, VLA-4, and If A-1 on CD}34+progenitor cells from bone marrow and peripheral blood during G-CSF-enhanced recovery. Exp Hemalol 1995; 23: 1535-42. |
| 335 | MorikaivaS,BalukP,Kaidoh T et al. Abnormalities inpericytes on bloodvessels and endotbelial sprouts in tumors. Am J Pathol 2002; 160 (3): 985-1000. |
| 336 | Morrow GR, HickokJT, RoscoeJA et al Differential effects ofparoxeti-ne on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program.J Clin Oncol2003; 21 (24): 4635-41. |
| 337 | Morrow GR, SbelkeAR, RoscoeJA et al. Management of cancer-related fatigue. Cancer Invest 2 005; 23:229-39. |
| 338 | Moss EL, Simpson JS, Pelletier G et al.An open-label study of the effects ofbupropion SR on fatigue, depression, and quality of life of mixed-site cancer patients and their partners. Psychooncology 2006, 15: 259-67. |
| 339 | Mross K,Stefanic M.Phase I study of the angiogenesis inhibitor BIBF1120 in pat.with advanced solid tumors.Clin.Can.Ress.2010,v.16,p.311-3110. |
| 340 | Nagahara Y, Shlina L, Nakata K. etal. Induction of mitochondria-involved apoptosis In estrogen receptor-negative cells by a novel tamoxifen derivative, ridaifen-B. Cancer Sci 2008;99(3):608-14. |
| 341 | Nazarewlcz R.R., Zenebe W.J., Parlhar A. etal. Tamoxifen induces oxidative stress and mitochondrial apoptosis via stimulating mitochondrial nitric oxide synthas. Cancer Res 2007;67(3): 1282^90. |
| 342 | Nicassio M., Wallston A., Callahan L. et al. The measurement of helplessness in rheumatoid arthritis: the development of the Arthritis Helplessness Index // J. Rheumatol. - 1985. - Vol. 12. - P. 462-467. |
| 343 | Nistico С Garufi C, Barni S et al Phase II study ofepirubicin and vinorelbine with granulocyte colony stimulating factor: a high-activity., dose-dense weekly regimen for advanced'breast cancer. Ann Oncol 1999; 10: 937-42. |
| 344 | O,hare T,Eide c.A.Proc.Nat.Acad.Sci.USA,2008,v.105,p.5507-5512 |
| 345 | O'Byrne K.J., Dalgleish A.G., Browning MJ. etal. The relationship between angiogenesis and the Immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 2000;36(2):151~-69. |
| 346 | Ogawa M.. Matsunaga T. Humoral regulation of hematopoietic stem cells. Ann N-YAS. 1999:17-23. |
| 347 | Okamura M, Yamawaki S, Akechi Т et at Psychiatric Disorders Following First Breast Cancer Recurrence: Prei silence, Associated Factors and Relationship to Quality oflifejpnj Clin Oncol 2005; 35 (6): 302-9. |
| 348 | Oostendorp Щ Sptizer E, Brand! M et al. Evidence for differences in the mechanisms by which antibodies against CD44 promote adhesion of erythroid and granulopoietic progenitors to marrow stromal cells. BrJ Haematol 1998; 101:436-45. |
| 349 | O'Regan R.M., Osipo C., Ariazi E. etal. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin Cancer Res 2006;12(7):2255-63. |
| 350 | O'ShaughnessyJ, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracyclinepretreated patients with advanced breast cancer: phase III trial results.} Clin Oncol 2002; 20:2812-23. |
| 351 | Osusky KL, Hattahan DE, FuA et al The receptor tyrosine kinase inhibitor SU11248 impedes endotbelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7 (3): 225-33. |
| 352 | OttiniL., MasalaG., D'Amico C. et al. BRCA 1 and BRCA 2 mutation status and tumor characteristics in mail breast cancer: a population-based study in Italy. Cancer Res 2003;63(2):342-7. |
| 353 | Ozols RF, Bundy BN, Fowler J et al, Randomised phase III study of cisplatin (CIS)/padiiaxel (РАС) versus carboplatin (CARBO)/PAC in optimal siage 111 epithelial ovarian cancer (ОС): A Gynaecologic Oncology Study Group Trial (GOG 158) [Abstract 13~3J. Proc Am Soc Clin Oncol 1999:18:356. |
| 354 | Pagani O, Sessa C. XoieF. el at Epidoxoruhicin and docetaxel as first-line chemoiherapy in patients with advanced breast cancer: a multicent-ricphase l-IIstiidy.Aim Oncol2000:11: 985-91. |
| 355 | Paik S, Bryant J, Tan-Chin E et al. Real-ivorM performance ofHER2 testing-National Surgical Adjiirani '}/сч7"/ and BoicelProject experience.} Natl Cancer Inst2002;94 (11): 852-/ |
| 356 | Palmier! C., Cheng G.J., Saji S. etal. Estrogen receptor beta in breast cancer. EndocrRelat Cancer 2002;9:1-13. Sommer S., Fuqua S.A. Estrogen receptor and breast cancer. Semin Cancer Biol 2001;! 1:339-52. |
| 357 | Pankaj T, Dejan M., Fumitake K. etal. Classical and novel prognostic markers for breast cancer and their clinical significance. Clin Med Insights Oncol - 2010; 15-34. |
| 358 | Papayannopoulou T, Priestley GV, Nakamoto B.Anti-VIA4/VCAM-l-induced mobilization requires cooperative signaling through the kit/mkit ligand pathway. Blood 1998; 91:2231 -9. |
| 359 | Papayannopoulou T. Hematopoietic Stem/Progenitor Cell Mobilization: a continuing quest for etiologic mechanisms. Ann N-Y AS. 1999: 187-95. |
| 360 | PatelN, Sun L, Moshinsky D et al.A selective and oral small molecule inhibitor of vascular epithelial groivth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability.} Phannacol Exp Tber 2003; 306 (3): 838-45. |
| 361 | Patrick D.L., Drossman D.A., Frederick I.O. et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure // Dig. Dis. Sci. - 1998. - Vol .43, No. 2. - P. 400-411. |
| 362 | Pauletti G, Godolpbin W, Press MF. Stjmon DJ. Detection and quanti-tation of HER-2/neu gene amplificatujr' hi human breast cancer archival material using fluorescence in siin hybridization. Oncogene 1996; 13 (1): 63-72. |
| 363 | Perez EA, Suman Vf, Davidson XE et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial] Clin Oncol2006; 24 (19): 3032-8. |
| 364 | Pham CD, Roberts TP, van Bruggen N et al Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial groivth factor. Cancer Invest 1998; 16 (4): 225-30. |
| 365 | PhilpottNJ, Prue RL, Marsh JC et al. G-CSF-mobilized CD34 peripheral blood stem cells are significantly less apoplotic then unstimulated peripheral blood CD34 cells: role ofG-CSF as survival factor. BrJ Haematol 1997; 97(1): 146-52. |
| 366 | Pincus T., Callahan L., Bradley L. et al. Elevated MMPI scores for hypochondriasis, depression and hysteria in patients with rheumatoid arthritis reflect disease rather than psychological status // Arthritis Rheum. - 1986. - Vol. 29. - P. 1456-1466. |
| 367 | Piper BF. The Groopman article reviewed. Oncology 1998; 12: 345-6. |
| 368 | Pisano E.D., Gatsonis С., Hendrick E. et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med 2005;353:1773-83. |
| 369 | Press Mf] Finn RS, Cameron D el al IIKR-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, andlapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res 2008; 14 (23): 7861-70. |
| 370 | PrestaLG, ChenH, O Connor SJ etal Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 199 7; 5 7 (20): 4593 -9. |
| 371 | Prosper F, Stroncek D, McCarthy JB et al. Mobilization and homing of peripheral blood progenitors is related to reversible doivnregulation of alpha4 beta1 integrin expression and function. J Clin Invest 1998; 101: 2456-61. |
| 372 | Prosper f] Stroncek D, McCarthy JB, Verfaillie CM. Mobilization and homing of peripheral blood progenitors is related to reversible downre-gulation ofalpha4 belal integrin expression and function.] Clin Invest '1998; 101 (11): 2456-67. |
| 373 | Prue G. Rank-in J, Cramp F et al. Fatigue in gynaecological cancer patients: a pilot study. Support Care Cancer 2006:14 (I): 78-83. |
| 374 | PruijtJF, Fihhe WE, Opdenakker G el al. Prevention ofinterteukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the Metalloproteinase gelatmase В (MMP-9).ProcNatlAcadSciUSA 1999; 96: 10863-8. |
| 375 | PtieloJM. Blanch JAtalaJ et al. Clinical factors associated with fatigue in hemalologic cancerpalients receiving stem-cell transplantation. EurJ Cancer 2006:42: I ~49-55. |
| 376 | Punt CJ, KeizerHJ, DoumaJ et al Trimetrexate as biochemical modulator of 5-fluorouracil/leucororin in advanced colorectal cancer: final results of a randomised European study. Ann Oncol 2002; 13: 81-6. |
| 377 | Ran S, Bivens C, Trieii Vet al Synergistic effect of albumin-bound paclitaxel (abraxa?ie) and anti-VEGF-A antibody (avastin) on growth of orthotopic MDA-M.B-231 breast tumors as well as lymphatic and pulmonary disease. Poster presented at the 2006 SABCS meeting, San Antonio, Texas, USA. 46. Pietras RJ, Chen H-W, MarquezDC. Improved anticancer therapy by targeting both breast tumor and host vascular cells with antiestrogen combined with antibodies to vascular endothelial growth factor. Poster presented at the 2006 SABCS meeting, San Antonio, Texas, USA. |
| 378 | Randell A., Bhalerao N., Nguyen T. et al. Quality of life in osteoporosis: reliability, consistency, and validity of the Osteoporosis Assessment Questionnaire // J. Rheumatol. - 1998. - Vol. 25, No. 12. - P. 1171-1179. |
| 379 | Rao U.S., Fine R.L., Scarborough G.A. Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 1994;48(2):287^92. |
| 380 | Ravens-Sieberer U., Bullinger M. Current approaches to measure the health-related quality of life in children // Ibid. - 1997. - No. 18. -P. 12-13. |
| 381 | Ream L, Richardson A. Fatigue: a concept analysis. Ml f Nurs Stud 1996:33:519-29. |
| 382 | Ren X., Kazis L, Meenan R. Short-form Arthritis Impact Measurement Scales 2: tests of reliability and validity among patients with osteoarthritis // Arthritis Care Res. - 1999. - Vol. 12, No. 3. - P. 163-173. |
| 383 | Renter K, Classen CC. RoscoeJA et al. Association of coping style, pain, age. and depression with fatigue in women with primaiy breast cancer. Psychooncolo^v 2006: 15: '"2-9. |
| 384 | Renter K, Harter M The concepts of fatigue and depression in cancer. EurJ Cancer Care (England) 2004:13:127-34. |
| 385 | Rivier C. Influence of immune signals on the bypothalamic-pituitary- axisoftbe rodent. Front Xeitrocjidocrinol /995: 16:151-82. |
| 386 | RL, LeuinJ, West WH et al open-label, III study of a 28 day oral of eniluractt plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line in patients mth metastatic advanced colorectal cancer.] Clin Oncol 2002; 20:1519-26. |
| 387 | Rodrigues L.R., Teixeira J.A., Schmitt F.L. etal. The role of osteopontin In tumor progression and metastasis in breast cancer. Cancer Epidemiol Biomark Prev 2007; 1087- 97. |
| 388 | Rohlff C, Blagosklonny M.V., Kyle E. etal. Prostate cancer cell growth Inhibition by tamoxifen Is associated with inhibition of protein kinase C and induction of p21(wafl/ cipl). Prostate 1998;37(1):51^9. |
| 389 | RomondEH, Perez EA, Bryant] et al Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1673-84. |
| 390 | RoscoeJA, Gary RM, HickokJTet al bydrocbloride (Paxifi) on fatigue in cancer patients receiving chemotherapy. Breast Cancer Res Treat 2005; 89 (3): 243-49. |
| 391 | Ryan Q, Ibrahim A, Cohen MH et al. FDA drug approval summary: la~ patinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008; 13 (10): 1114-9. |
| 392 | Safa A.R., Roberts S., Agresti M., Fine R.L. Tamoxifen aziridine, a novel affinity probe for P-glycoprotein In multidrug resistant cells. Biochem Biophys Res Commun 1994;202(1):606-12. |
| 393 | SaltzLB, CoxJV, С et al. Innotecan plus fluorouracil and leu- covorin for metastatic colorectal cancer. N J Med 2000; 343: 905-14. |
| 394 | Sandier'AB, NemunaitisJ, Denham С et al. Ill trial ofgemcitabi- neplus cisplatin versus alone in patients with locally advanced or metastatic non-small cell lung cancer.] Clin Oncol 2000; 18:122-30. |
| 395 | Sarhitt N} Д Nelson KA et al. Metbylpbenidate for fatigue in ad- vanced cancer: a prospective open-label pilot AmJ Care 2001; 18:187-92. |
| 396 | sato H,Sasazuki T,Tsunoo H/Proc.Japan Acad - 1973. - Уо1. 49, N 7. - Р. 549-554. о1. 19. - Р. 2753-2758 |
| 397 | Sauter G, Lee J, Bartlett JM et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.] Clin Oncol2009;27 (8): 1323-33. |
| 398 | Scarlatti E, Bauvy C., Ventrutl A. etal. Ceramide™mediated macroautophagy involves inhibition of protein kinase B and up-regulation ofbeclin 1. J Biol Chem 2004;279(18):18384-91. |
| 399 | SchechterAL, Stern DP, Vaidyanathan L et al. The neu oncogene: an erb-B'-related gene encoding a 185,000-Mr tumour antigen. Nature 1984; 312 (5994): 513-6. |
| 400 | Schiller IH, Harrington D, CP et al Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N EnglJ Med 2002; 346:92-8. |
| 401 | Schirrmacher S.Congress of Clinical Chemistry and laboratory Medicine-2003/08-10.10,Aahen - Р 4.54. |
| 402 | Schirrmacher S.Congress of Clinical Chemistry and laboratory Medicine-2003/08-10.10,Aahen - Р 4.54. |
| 403 | Schlotter CM., Vogt U., Allgayer H. etal. Molecular targeted therapies for breast cancer treatment. Breast Cancer Res 2008;10:211. |
| 404 | Schneider-Merck T, Trepel M. Recent Cancer Res 2010; 184:45-59. |
| 405 | Schwartz AL, MonM} Goo R et al Exercise reduces in women with breast cancer receiving chemotherapy. Med Sci Sports Exerc 2001; 33: 718-23. |
| 406 | Schwartz AL, Thompson JA, MasoodN. Interferon-induced fatigue in patients with melanoma: a pilot of exercise metbylpbenidate. Oncol Nurs Forum 2002; 29: E85-E90. |
| 407 | Schwartzberg LS, Franco SX, Florence A et al as first-line therapy for HER-2+ receptor-positive breast cancer. Oncologist 2010; 15 (2): 122-9. |
| 408 | Semba K, Kamata N, Toyoshima K, Yamamoto Т. А v-егЪВ-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene is in a adeno-carcinoma.ProcNatlAcadSciUSA 1985; 82 (19): 6497-501. |
| 409 | Servaes P, Gielissen MF, Verbagen S et al The course of severe fatigue in disease-free breast cancer patients: a study. Psychoonco-logy 2007; 16: 787-95. |
| 410 | Servaes P, Verbagen C, G, between fatigue, ne-uropsychological functioning, and physical functioning for carcinoma. Cancer 2 002; 95:2017-26. |
| 411 | Servaes P, Verbagen C, Scbreuder В et at treatment for malignant benign bone and soft tumors.] Pain Symptom Ma- 2003; 26:1113-22. |
| 412 | Sharif T.R., Sharif M. A novel approach for examining the antl-proliferative effect of protein kinase C inhibitors against human astrocytoma cells. Int J Oncol 1998;13(4):685^92. |
| 413 | ShenL.Z.,HuaY.B.,YuX.M. Tamoxifen can reverse multidrug resistance of colorectal carcinoma In vivo. World J Gastroenterol 2005;ll(7):1060-4. |
| 414 | Shepherd FA, DanceyJ, Ramlau R et al Prospective randomized trial ofdocetaxel versus best supportive care in patients with non-small cell lung cancer previously with platinum-based chemotherapy.} Clin Oncol 2 000; 18:2095-103. |
| 415 | Sherbourne C., Stewart A. The MOS social support survey // Soc. Sci. Med. - 1991. - Vol. 32. - P. 705-714. |
| 416 | Shimoda К, Okamura S, Harada N el al. High-frequency granuloid colony-forming ability ofG-CSF receptor possessing CD34 antigen positive human umbilical cord blood hematopoietic progenitors. Exp Hematology 1992; 23:226-8. |
| 417 | ShinjoK, TakeshitaA, OhnishiK, OhnoR. Expression of granulocyte colony-stimulating factor receptor increases with differentiation in myeloid cells by a newly devised quantitative flow-cytometric assay. BrJ Haema-tol 1995;91: 783-94. |
| 418 | Sieg A,Thoms C,Luthgens K.- Int.J.. Со1огесга1 Dis. 1999. - Уо1. 14. - Р. 267-271. |
| 419 | Sieg A,Thoms C,Luthgens K.- Int.J.. Со1огесга1 Dis. 1999. - Уо1. 14. - Р. 267-271. |
| 420 | Skaane P., Balleyguier C., Diekmann F. et al. Breast lesion detection and classification: comparison of screen-film mammography and full-field digital mammography with soft-copy reading - Observer Performance Study. Radiology 2005; 237:37-44. |
| 421 | Skaane P., Skjennald A. Screen-film mammography versus full-field digital mammography with soft-copy reading: randomized trial In a population-based screening program - the Oslo II Study. Radiology 2004;232:197-204. |
| 422 | Skaane P., Young K., Skjennald A. Population-based mammography screening: comparison of screen-film and full-field digital mammography with soft-copy reading - Oslo I Study. Radiology 2003;229:877^84. |
| 423 | Slamon DJ, Clark G-M. Amplification ofc-erbB-2 human breast tumors? Science 1988; 240 (4860): 1796-8. |
| 424 | Slamon DJ, Clark GM. Wong SG et al. Human cancer: correlation of relapse and survival with oftheHER-2/neu oncoge-ne. Science 1987; 235 (4785): 177-82. |
| 425 | Slamon DJ, Godolpbin W. JonesI A et al, of the HER-2/neu pro-to-oncogene in human breast ovarian cancer. Science 1989; 244 (4905): '707-12. |
| 426 | Slamon DJ, Leyland-Jones B, S et al. Use of chemotherapy plus a monoclonal antibody HER2 for cancer overexpressesHER2.NEnglJMed2001; 344 (11): 783-92. |
| 427 | SmetsEMA, VisserMRM, Wittems-GrootAFMN et al. and radio- therapy, (B): experience in patients 9 months following treatment. BrJ Cancer 1998; 73:907-12. |
| 428 | Song L, Xu Z., Zhang C. etal. Up-regulation of the HSP72 by Foxal in MCF-7 human breast cancer cell line. Biochem Blophys Res Commun 2009;386(l):30-4. |
| 429 | Spelleden ER} VerbeekJH, UitterboeveAL et al. Cancerjattgue, tbe return of patients to work: a prospective cobon study. EurJ Cancer 2003; 39:1562^7. 88. Stein KD} Martin SCf Hann DM et al A multidimensional measure of fatigue for use cancer patients. Cancer Pract 1998; 6:143-52. |
| 430 | Spertus J.A., Winder J.A., Dewhurst T.A. et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease // J. Am. Coll. Cardiol. - 1995. - Vol. 25, No. 2. - P. 333-341. |
| 431 | Sprangers M.A., Cull A., Bjordal K. et al. The European Organization for Research and Treatment of Cancer approach to quality of life assessment: guidelines for developing questionnaire modules // Qual. Life Res. - 1993. -Vol. 2. - P. 287-295. |
| 432 | Starfield B. Adolescent health status measurement: development of the Child Health and Illness Profile // Pediatrics. - 1993. - Vol. 91. -P. 430-435. |
| 433 | Stark D., Kiely M., Smith A. et al. Anxiety disorders in cancer patients: their nature, associations, and relations to quality of life. J Clin Oncol 2002;20:3 137-48. 6, Greer S. Mind-body research in psychooncology. Advanc Mind- Body Med 1999;15:236-81. |
| 434 | Stebbing J., Ellis P., Tutt A. inhibitors in BRCAl-/BRCA2-associated and triple-negative breast cancers. Future Oncol 2010;485-6. |
| 435 | Sura W} Murpby SO, Gonzales 1, Level of fatigue in women receiving dose-dense versus chemotherapy for cancer: a pilot stu- dy. Oncol Nurs Forum 2006; 33 (5): 1015-21. |
| 436 | Svedlund J., Sjodin L, Dotevall G. GSRS-a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease // Dig. Dis. Sci. - 1988. - Vol. 33, No. 2. - P. 129-134. |
| 437 | Tanaka K., Iwamoto S., Gon G. etal. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000;6:127-34. |
| 438 | Tan-Chin E, Yothers G. RomondE etal. Assessment of cardiac dysfunction in a trial comparing doxorubicin and cyclophosphami- de followed by paclitaxel with or without trastuzumab as adjuvant the-in node-positive, human epidertnal growth factor receptor 2-ove-rexpressing cancer: NSABP B-31.J din Oncol 2005; 23 (31): 7811-9. |
| 439 | Taneja P., Maglic D., Kai F. etal. Classical and novel prognostic markers for breast cancer and their clinical significance. Clinical Medicine Insights. Oncology 2010;4:15-34. |
| 440 | Tanner M, GancbergD, DiLeoA et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am JPathol 2 000; 157 (5): 1467-72. |
| 441 | Tarella C, Benedetti G, Caracciolo D et al. Boyh early and committed haematopoietic progenitors are more frequent in peripheral blood then in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF.BrJHaematol 1995; 91:535-43. |
| 442 | Ten W, Gore M, CarmicbaelJ et al Topotecan versus paclitaxel for tbe treatment of recurrent epithelial ovarian cancer.] Clin Oncol 1997; 15:2133-93- |
| 443 | Terada T. Primary multiple extra-GIST of the omentumwith different mutationes of c-kit gene.World J.Gastr.2008,v.14,p.7256-7259. |
| 444 | The Canadian Burden of Illness Study Group. Burden of illness of multiple sclerosis: Part II: Quality of life // Can. J. Neurol. Sci. - 1998. -Vol. 25. - P. 31-38. |
| 445 | Theunissen N., Vogels Т., Коортап Н. The proxy problem: child report versus parent report in health-related quality of life research // Qual. Life Res. - 1998. - Vol. 7, No. 5. - P. 387-397. |
| 446 | Thomas P, Castelnau O, Paillotin D et al. Phase II trial of paclitaxel carboplatin in small cell cancer: a Groupe Francais de Pneumo-Cancerologie study.] Clm Oncol 2001; 19:1320-5. |
| 447 | Thorner R.M., Russel J.T. Principles and procedures in the evaluation of screening for disease.- Washington: Gov. Print. Office, 1961.-24 p. |
| 448 | TongRT, Boucher Y,Kozin SVetcd. Vascular normalization by vascular endotbelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64 (11): 3731 -6. |
| 449 | Torok-Storb В et al. Dissecting the marrow microenvironment ISH-EHA 1999:164-9- |
| 450 | Tsuji K, Ebihara Y. Expression ofG-CSF receptor on myeloid progenitors. LeukLytnpboma2001;42 (6): 1351-7. |
| 451 | Tugwell P, Bombardier C, Buchanan W. et al The MACTAR patient preference disability questionnaire // J. Rheumatol.- 1987.- Vol. 14.- P. 446-451. |
| 452 | Uchida N, He Д TsukamotoA. The Unexpected GO/G1 Cell Cycle Status of Mobilized Hematopoietic Stem Cells From Peripheral Blood. Blood 1997; 89 (2): 465-72. |
| 453 | Urruticoechea A., Smith I.E., Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005;23(28):7212-20. |
| 454 | Vainio H. Targeting angiogenesis - a novel mode in cancer chemoprevention. Asian Pac J Cancer Prev 2003;4(2):83-6. |
| 455 | Van Cutsem E, Findlay M} Osterwalder В et al. Capecitabine, an oral fluoropyrimidine activity in advanced colorectal cancer: of a II study J Clin Oncol 2000; 18:1337-45. |
| 456 | Varni J. Burwinkle Т., Katz E. et al The PedsQI^ in pediatric cancer: reliability and validity of the Pediatric Quality of Life Inventoryu; Generic Core Scales, Multidimensional Fatigue Scale and Cancer Module // Cancer. - 2002. - Vol. 94. - P. 2094-2106. |
| 457 | Varni J. Seid M., Kurtin P. The PedsQLO 4.0: Reliability and validity of the Pediatric Quality of Life Inventoi-уд Version 4.0 Generic Core Scales in healthy and patients populations // Med. Care. - 2001 -Vol. 39. - P. 800-812. |
| 458 | Varni J., Seid M., Kurtin P. Pediatric health-related quality of life measurement technology: a guide for health care decision makers // J. Clin. Outcomes Manage. - 1999. - Vol. 6, No. 4. - P. 33-40. |
| 459 | VetttlardJ, DrouetM, Neildez-nguyen TMA el al. Interteukine-8 acts as a strong peripheral blood granulocyte-recruiting agent rather then as a hematopoietic progenitor cell-mobilizing factor. J Hematoter Stem Cell Res 1999; 8:365-79. |
| 460 | Viestinen M,Lasota J.GIST pathology and prognosis at different sites.Semin.Diagn.Pathol.2006,v.23,p.70-83 |
| 461 | Vogels T. Measuring health-related quality of life in children: the development of the TACQOL-parent form // Qual. Life Res. - 1998. -Vol. 7, No. 5. - P. 457-465. |
| 462 | Von PawelJ, Schiller JH, FA et al Topotecan versus cyclop-hosphamide, doxorubicin vincristine for tbe treatment of recurrent cell lung cancer J Clin Oncol 1999; 17:658-67. |
| 463 | Vosseler S, Mirancea N, Bohlen P et al Angiogenesis inhibition by vascular endothelial groivth factor receptor-2 blockade reduces stromal matrix metallo-proteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 2005; 65 (4): 1294-305. 38. Yuan F, Chen Y, Dettian M et al Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular'permeability factor antibody. Proc NatlAcadSci USA 1996;93 (25): 14765-70. |
| 464 | Wada T, MyersJN, Kokai Y et al. Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins. Oncogene 1990; 5 (4): 489-95. |
| 465 | Wahrborg P., Emanuelsson H. The cardiac health profile: content, reliability and validity of a new disease-specific quality of life questionnaire // Coron. Artery Dis. - 1996 - Vol. 7, No. 11. - P. 823-829. |
| 466 | Wang C., Mayo N., Fortin P. The relationship between health related quality of life and disease activity and damage in systemic lupus erythe-matosus // J. Rheumatol. - 2001. - Vol. 28. - P. 525-532. |
| 467 | Ware J., Snow K., Kosinski M. et al. SF-36 health survey: Manual and Interpretation Guide. - Boston, 1993. - 143 p. |
| 468 | Watanabe T, Kawano Y, Kanamam S et al. Endogenous inlerleukin-8 (IL-8) surge in granulocyte colony-stimulatingfactor-induced peripheral blood stem cell mobilization. Blood 1999; 93 (4): 1157-63. |
| 469 | WatkinsLM}MaierSF} GoehlerlE. Cytokine-to-brain communication: a reidew of alternative Life Sci 1995; 57:1011 -26. |
| 470 | Watson M., Greer S., Rowden L. et al. Relationships between emotional control, adjustment to cancer and depression and anxiety in breast cancer patients. Psychol Medl991;21:51-7. |
| 471 | Wedam SB, Low]A, Yang SX et al Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24 (5): 769^77. |
| 472 | Wildiers H, Guetens G, De Boeck G et al Effect ofantivascular endothelial groivth factor treatment on the intratmnoral uptake ofCPT-11. BrJ Cancer 2003; 88 (12): 1979-86. |
| 473 | Willett CG, Bouchej Y. di Tomaso E et al Direct ei idence that the \ "EGF-specific antibody bevacizumab has antii 'oscular effects hi human rectal cancer. Nat Med 2004; 10 (2): 145-7. |
| 474 | Wolfe F., Skevington S. Measuring the epidemiology of distress: the Rheumatology Distress Index // J. Rheumatol. - 2000. - Vol. 27. - P. 2000-2009. |
| 475 | Wolff АС, Hammond ME. SchwartzJN et al. American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. JClin Oncol2007; 25 (1): 118-45. |
| 476 | WozniakAJ, CrowleyJJ, SP et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced nonsmatt cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol 1998; 16:2459-65. |
| 477 | Yamaguchi M, Ikebuchi K, Hirayama F et al. Different adhesive characteristics andVIA-4 expression ofCD34 (+) progenitors in GO/G1 versus S*G2/M phases of the cell cycle. Blood 1998; 92 (3): 842-8. |
| 478 | Yang C.H., Cheng A.L., Yen K.H. etal. High dose tamoxifen plus cisplatin and etoposide in the treatment of patients with advanced, inoperable nonsmall cell lung carcinoma. Cancer 1999;86(3):415-20. |
| 479 | Yerushalmy J. Statistical problems in assessing methods of medical diagnosis with special reference to X-ray techniques // Publ. Health Rep. – 1947. – Vol. 62, N 10.- P. 1432 – 1449. |
| 480 | Yirmiya R, Y} О et al. Effects of antidepressant drugs on tbe behavioral and physiological responses to lipopolysaccharide (IPS) in rodents. Neuropsycbopbarmacology. 2001; 24:531 -44- |
| 481 | Young KE, White CA, Tbe prevalence moderators of fatigue in people who have been successfully treated for cancer. J Psychosom Res 2006; 60:29-38. |
| 482 | Yurtsever S, Tbe of fatigue in Turkish patients receiving chemotherapy. Oncol Nurs Forum 2007; 34 (3): 721-3. |
| 483 | Zakhartseva L.M., Gorovenko N.G., Podolskaya 8.V. etal. Breast cancer immunohistochemlcal features in young women with BRCA 1/2 mutations. Exp Oncol 2009;31:174-8. |
| 484 | Zhou Y, Eppenberger-Castorl S., Marx C. etal. Activation of nuclear factor-kappaB (NFkappaB) Identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 2005;37(5): 1130-44. |
| 485 | Zigmond A., Snaith R. The Hospital Anxiety and Depression Scale // Acta Psychiatr. Scand. - 1983. - Vol. 67. - P. 361-370. |
Еще по теме Список литературы:
- Список рекомендуемой литературы Основная литература
- Список рекомендуемой литературы и веб-сайты
- Список литературы и материалов
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы.
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы:
-
Детская онкология -
Кардиоонкология -
Лечение онкологических заболеваний -
Онкогастроэнтерология -
Онконефрология -
Паллиативная медицина -
-
Акушерство и гинекология -
Анатомия -
Андрология -
Биология -
Болезни уха, горла и носа -
Валеология -
Ветеринария -
Внутренние болезни -
Военно-полевая медицина -
Восстановительная медицина -
Гастроэнтерология и гепатология -
Гематология -
Геронтология, гериатрия -
Гигиена и санэпидконтроль -
Дерматология -
Диетология -
Здравоохранение -
Иммунология и аллергология -
Интенсивная терапия, анестезиология и реанимация -
Инфекционные заболевания -
Информационные технологии в медицине -
История медицины -
Кардиология -
Клинические методы диагностики -
Кожные и венерические болезни -
Комплементарная медицина -
Лучевая диагностика, лучевая терапия -
Маммология -
Медицина катастроф -
Медицинская паразитология -
Медицинская этика -
Медицинские приборы -
Медицинское право -
Наследственные болезни -
Неврология и нейрохирургия -
Нефрология -
Онкология -
Организация системы здравоохранения -
Оториноларингология -
Офтальмология -
Патофизиология -
Педиатрия -
Приборы медицинского назначения -
Психиатрия -
Психология -
Пульмонология -
Стоматология -
Судебная медицина -
Токсикология -
Травматология -
Фармакология и фармацевтика -
Физиология -
Фтизиатрия -
Хирургия -
Эмбриология и гистология -
Эпидемиология -